People | December 14, 2023
Moderna Chief Commercial Officer steps down, President to look over pipeline strategy
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches have demonstrated considerable increases in disease detection rates over other approaches
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
The company will collaborate with U.S.-based colleagues to help life sciences companies improve commercial effectiveness
Subscribe To Our Newsletter & Stay Updated
